Dr TEOH Yuen Chun Jeremy    
張源津

Associate Professor
MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery)

Urology
(852) 3505 2625 / Appointment 3946 6088
jeremyteohadd this for spam@add this for spamsurgery.cuhk.edu.hk
@jteoh_hk
H-5184-2016
0000-0002-9361-2342

Biography

Dr Jeremy Teoh is currently the Assistant Dean (External Affairs) and Associate Professor of the Faculty of Medicine, The Chinese University of Hong Kong (CUHK). He is also the Clinical Director of Urology, and Director of Robotic Services, at the CUHK Medical Centre. In 2021, he was awarded the Ten Outstanding Young Persons Award (Hong Kong) and the SIU-Innovators Award. In 2023, he was appointed as an Adjunct Professor at the Medical University of Vienna. In 2024, he received the World Chinese Urological Society Rising Star Award.

Jeremy is an oncological surgeon with primary interest in bladder cancer and upper tract urothelial carcinoma. Previously, he conducted a randomised trial comparing between bipolar and monopolar transurethral resection of bladder tumour (TURBT) and showed that bipolar TURBT was able to achieve a higher detrusor sampling rate than monopolar TURBT. He has also developed a global consensus statement on en bloc resection of bladder tumour (ERBT). A total of 99 statements reached consensus and they have become the standard reference for urologists practising en bloc resection globally. In 2024, he published the results of the EB-StaR study, which is a multi-centre randomised trial demonstrating that ERBT could reduce the 1-year recurrence rate from 38.1% to 28.5% for patients with ≤3cm non-muscle-invasive bladder cancer (NMIBC). He also completed a phase 2 clinical trial on modified en bloc resection for large bladder tumours (>3cm), showing that modified ERBT could achieve a >90% rate of complete resection for NMIBC and proper staging for MIBC. He is also leading the Global ERBT Registry, which has >100 centres joining and >3000 patients being recruited so far. He is also the principal investigator of a randomised trial investigating the role of kidney-sparing sparing for patients with upper tract urothelial carcinoma. He is currently serving as a panel member of the European Association of Urology (EAU) Guidelines on NMIBC and Upper Tract Urothelial Carcinoma. He is also serving as an Associate Editor for the prestigious journal European Urology Oncology.

Jeremy has received numerous research grants with a total funding of more than 15 million USD. He has published more than 500 articles in peer-reviewed journals such as Nature Reviews Disease Primer, European Urology, Annals of Surgery, and Nature Reviews Urology. He has been a reviewer for more than 60 journals, including Lancet Oncology, Cell Reports Medicine, Nature Communications, and European Urology. He was the Chairperson of the Younger Fellows Chapter of the College of Surgeons of Hong Kong (2019-2021), the Chair of the Young Fellows Chapter of the Hong Kong Academy of Medicine (2021-2022), and he has been the Director of the Lions Kidney Educational Centre & Research Foundation since 2017. He is also the founder of the UroSoMe (Urology Social Media) working group and he believes that social media plays an important role in the modern era of medicine.

Research Interests

• Urinary biomarkers for bladder cancer
• Tumour heterogeneity and molecular classification of bladder cancer
• Transurethral en bloc resection of bladder tumour
• Androgen deprivation therapy for prostate cancer
• Advanced robotic surgery for urological cancers
• Kidney-sparing surgery for upper tract urothelial carcinoma

Additional Information

• Clinical Director of Urology, CUHK Medical Centre
• Director of Robotic Services, CUHK Medical Centre
• Congress Chair, Societe Internationale d’Urologie (SIU)
• Director of the Lions Kidney Educational Centre & Research Foundation
• Panel member of the EAU Guidelines on Non-Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma
• Council member of the Hong Kong Society of Transplantation
• Chairperson of the Younger Fellows Chapter of the College of Surgeons of Hong Kong (2019-2021)
• Chair of the Young Fellows Chapter, Hong Kong Academy of Medicine (2021-2022)
• Steering Committee Member of the Asian Urological Surgery Training & Education Group
• Founder of the UroSoMe (Urology Social Media) working group
• Consulting editor for European Urology
• Associate editor for European Urology Oncology

Selected Publications

1. Zhao H, Lin N, Ho VWS, Liu K, Chen X, Wu H, Chiu PK, Huang L, Dantes Z, Wong KL, Chau HF, Ko IC, Wong CH, Leung DK, Yuen SK, Wu D, Ding X, Ng CF, Teoh JY*. Patient-Derived Bladder Cancer Organoids as a Valuable Tool for Understanding Tumor Biology and Developing Personalized Treatment. Adv Sci (Weinh). 2025;12(13):e2414558. *Corresponding author (Impact factor: 14.1)
2. Masson-Lecomte A, Birtle A, Pradere B, Capoun O, Compérat E, Domínguez-Escrig JL, Liedberg F, Makaroff L, Mariappan P, Moschini M, Rai BP, van Rhijn BWG, Shariat SF, Smith EJ, Teoh JYC, Soukup V, Wood R, Xylinas EN, Soria F, Seisen T, Gontero P. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: Summary of the 2025 Update. Eur Urol. 2025;87(6):697-716. (Impact factor: 25.3)
3. Teoh JY*, Cheng CH, Tsang CF, Kai-Man Li J, Kwun-Chung Cheng B, Hoi-Chak Chan W, et al. Transurethral En Bloc Resection Versus Standard Resection of Bladder Tumour: A Randomised, Multicentre, Phase 3 Trial. Eur Urol. 2024;86(2):103-11. *Corresponding author (Impact factor: 25.3)
4. Powles T, Albiges L, Bex A, Comperat E, Grunwald V, Kanesvaran R, Kitamura H, McKay R, Porta C, Procopio G, Schmidinger M, Suarez C, Teoh J, de Velasco G, Young M, Gillessen S, clinicalguidelines@esmo.org EGCEa. Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35(8):692-706. (Impact factor: 56.7)
5. Teoh J, Bhatt NR, Cucchiara V, Garcia Rojo E, Gauhar V, Mercader C, et al. Best Practice in Using Social Media: The European Association of Urology Position Statement. Eur Urol. 2024. (Impact factor: 25.3)
6. Song Y, Teoh JY, Choi KS, Qin J. Dynamic Loss Weighting for Multiorgan Segmentation in Medical Images. IEEE Trans Neural Netw Learn Syst. 2024;35(8):10651-62. (Impact factor: 13.7)
7. Bhatt NR, Garcia Rojo E, Gauhar V, Mercader C, Cucchiara V, Bezuidenhout C, van Gurp M, Bloemberg J, Teoh JY, Ribal MJ, Giannarini G, European Association of Urology Guidelines Office Dissemination C. The Intersection of Artificial Intelligence and Social Media in Shaping the New Digital Health Frontier: Powers and Perils. Eur Urol. 2024;85(3):183-4. (Impact factor: 25.3)
8. Dyrskjot L, Hansel DE, Efstathiou JA, Knowles MA, Galsky MD, Teoh J, Theodorescu D. Bladder cancer. Nat Rev Dis Primers. 2023;9(1):58. (Impact factor: 97.0)
9. Liu AQ, Chiu PK, Yee SC, Ng CF, Teoh JY. SARS-CoV-2 infection correlates with male benign prostatic hyperplasia deterioration. J Intern Med. 2023;294(6):775-83. (Impact factor: 11.1)
10. Zhang K, Teoh J, Laguna P, Dominguez-Escrig J, Barret E, Ramon-Borja JC, Muir G, Bohr J, de Reijke TM, Pelechano Gomez P, Ng CF, Sanchez-Salas R, de la Rosette J. Effect of Focal vs Extended Irreversible Electroporation for the Ablation of Localized Low- or Intermediate-Risk Prostate Cancer on Early Oncological Control: A Randomized Clinical Trial. JAMA Surg. 2023;158(4):343-9. (Impact factor: 14.9)
11. Wang G, Choi KS, Teoh JY, Lu J. Deep Cross-Output Knowledge Transfer Using Stacked-Structure Least-Squares Support Vector Machines. IEEE Trans Cybern. 2022;52(5):3207-20. (Impact factor: 19.1)
12. Teoh JY*, Kamat AM, Black PC, Grivas P, Shariat SF, Babjuk M. Recurrence mechanisms of non-muscle-invasive bladder cancer - a clinical perspective. Nat Rev Urol. 2022;19(5):280-94. *Corresponding author (Impact factor 16.4)
13. Teoh JY, Yip TC, Lui GC, Wong VW, Chow VC, Ho TH, et al. Risks of AKI and Major Adverse Clinical Outcomes in Patients with Severe Acute Respiratory Syndrome or Coronavirus Disease 2019. J Am Soc Nephrol. 2021;32(4):961-71. (Impact factor: 15.0)
14. Teoh JY*, Castellani D, Mercader C, Sierra A, Heldwein FL, Chan EO, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. Eur Urol. 2021;80(4):442-9. *Corresponding author (Impact factor: 25.3)
15. Tan YQ, Wang Z, Yap QV, Chan YH, Ho RC, Hamid A, Landaluce-Olavarria A, Pellino G, Gauhar V, Chand M, Wroclawski ML, Hameed BMZ, Ling SK, Sengupta S, Gallo G, Chiu PK, Tanidir Y, Tallada MPV, Garcia BN, Colleoni R, Abiddin ZAZ, Campi R, Esperto F, Carrion D, Elterman D, Chung ASJ, Ng ACF, Moschini M, Rivas JG, Mayol J, Teoh JY*, Chiong E*. Psychological Health of Surgeons in a Time of COVID-19: A Global Survey. Ann Surg. 2021. *Co-corresponding authors. (Impact factor 13.8)
16. Teoh JY, MacLennan S, Chan VW, Miki J, Lee HY, Chiong E, et al. An International Collaborative Consensus Statement on En Bloc Resection of Bladder Tumour Incorporating Two Systematic Reviews, a Two-round Delphi Survey, and a Consensus Meeting. Eur Urol 2020. (Impact factor: 25.3)
17. Teoh JY*, Ong WLK, Gonzalez-Padilla D, Castellani D, Dubin JM, Esperto F, et al. A Global Survey on the Impact of COVID-19 on Urological Services. Eur Urol 2020. *Corresponding author (Impact factor: 25.3)
18. Teoh JY, Huang J, Ko WY, Lok V, Choi P, Ng CF, et al. Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita. Eur Urol 2020. (Impact factor: 25.3)
19. Rodriguez Socarrás M, Loeb S, Teoh JY, Ribal MJ, Bloemberg J, et al. Telemedicine and Smart Working: Recommendations of the European Association of Urology. Eur Urol 2020. (Impact factor: 25.3)
20. Chiu PK, Ng CF, Semjonow A, Zhu Y, Vincendeau S, Houlgatte A, Lazzeri M, Guazzoni G, Stephan C, Haese A, Bruijne I, Teoh JY, et al. A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings. Eur Urol 2019; 75(4):558-561. (Impact factor: 25.3)

The full list of publications can be accessed here.